targeting acute, life threatening and chronic inflammatory diseases with new and selective inhibitors of the C5a/C5aR signaling pathway of the immune system's complement cascade.
InflaRx is developing highly specific therapeutics targeting the C5a/C5aR signaling axis of the complement system. InflaRx has made breakthrough discoveries in the area of selective anti-C5a antibody generation and C5a receptor (C5aR) inhibitors.
InflaRx focuses on diseases with high unmet medical need. Vilobelimab, the company's first-in-class anti-human C5a monoclonal antibody is currently being developed in several chronic inflammatory diseases, as well as oncology and for the treatment of critically ill COVID-19 patients.
Gohibic (vilobelimab) - FDA has issued an emergency use authorization (EUA) to treat certain critically ill COVID-19 patients.
The latest information on InflaRx share price with interactive charts, comparative analysis, historic figures and latest trade price is available here.
Jena, Germany, September 11, 2023 – InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering ...
Jena, Germany, August 30, 2023 – InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering ant...
Jena, Germany, August 10, 2023 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharma-ceutical co...
Jena, Germany, June 28, 2023 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical compa...
Jena, Germany, June 21, 2023 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing a...
Jena, Germany, May 11, 2023 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing an...
Jena, Germany, April 18, 2023 – InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopha...
Jena, Germany, April 14, 2023 – InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopha...
Jena, Germany, April 11, 2023 – InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopha...
Jena, Germany, April 11, 2023 – InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopha...
